They haven't switched nothing Gouldiani - mpl works to arrest...

They haven't switched nothing Gouldiani - mpl works to arrest tumours, including late stage resistant ("refractory") tumours that are beyond standard of care,and this has been shown successfuily in the lab by ONJCRI against 27 human cancers including, ovarian, lung, breast, brain, bowel, among others. Working on coming up with an optimal pill/dose for dogs and humans is a very tricky thing in this mTOR mechanism related medication business where dose levels have to be just right.The ongoing dog cancer trial is delivering the desired results. Last year's trial that preceeded the Elanco pull-out was successful against the tumours but still left some critical issues to be overcome - but are now under control. BTW It's pretty common these days to use dog cancer trials to lead and guide human cancer trials.

.I note that you're heavily into resource explorers, and while there are some similarities in both resource explorers and biotechs, there are some really crucial differences.

And make sure you read NZT's excellent overview above. Note, he's very experienced with biotechs.


Cheers